Sara Jane Demy is the CEO & Founder of Demy-Colton, a leading biotech and life sciences events organization.
As part of BioPharm International's continuing coverage from the BIO International Convention 2026, Sara Jane Demy, CEO of Demy-Colton, discusses how artificial intelligence, global collaboration, and renewed investment could help improve drug development success rates and accelerate innovation.
As part of BioPharm International's continuing coverage from the BIO International Convention 2026, Sara Jane Demy discusses signs of renewed investment activity and why inclusive scientific leadership remains essential to advancing drug development.
At BIO International Convention 2026, Sara-Jane Demy discusses improving biotech investment, renewed NIH support for emerging companies, and why capital access remains one of the industry's biggest priorities.
